Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 15, 2007 Brian Lawler	King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years.
The Motley Fool April 2, 2007 Brian Lawler	Pain Therapeutics Pares Shares The small drugmaker announces a share buyback.
The Motley Fool May 28, 2008 Brian Lawler	King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another.
The Motley Fool November 10, 2005 W.D. Crotty	Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%.
The Motley Fool December 7, 2007 Brian Lawler	Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy.
The Motley Fool May 2, 2007 Brian Lawler	Another Free Quarter of Pain If the Remoxy abuse-resistant platform technology produces more positive clinical trial results later in the year, investors should have plenty to cheer about.
The Motley Fool November 5, 2007 Brian Lawler	King's Abuse-Resistant Bet King Pharmaceuticals signs a development deal with Acura Pharmaceuticals to produce abuse-resistant painkillers. Investors, take note.
The Motley Fool August 25, 2008 Brian Lawler	King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market.
The Motley Fool March 3, 2009 Robert Steyer	Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company.
The Motley Fool September 18, 2007 Brian Lawler	Direct Your Attention to DURECT Promising drug test results make DURECT a company to watch. The tiny drugmaker has a host of important milestones coming up over the next year.
The Motley Fool April 1, 2008 Brian Lawler	A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics.
The Motley Fool August 14, 2009 Brian Orelli	The Real King of the Drug Pushers King Pharma is first up with a tamper-resistant morphine tablet.
The Motley Fool December 11, 2008 Brian Orelli	A Painful Letter from the FDA The FDA smacked down King Pharmaceuticals and Pain Therapeutics with a complete response letter for their application to market Remoxy, an abuse-resistant controlled-release form of oxycodone.
The Motley Fool September 12, 2008 Brian Lawler	King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders.
The Motley Fool June 11, 2008 Brian Lawler	Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals?
The Motley Fool May 29, 2007 Brian Lawler	The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids.
The Motley Fool February 28, 2008 Brian Lawler	Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful.
The Motley Fool June 24, 2011 Brian Orelli	Come on, Pfizer, Not Even a Little Hint? Remoxy is rejected, but why?
The Motley Fool August 14, 2008 Brian Lawler	A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA.
The Motley Fool November 13, 2006 Brian Lawler	King Not Loving Its Shareholders King Pharmaceuticals appears to be a company with stagnating operations, trying to grow sales via licensing or acquiring new drugs, with (at best) a shaky handling of its accounting practices. Investors, take note.
The Motley Fool October 12, 2010 Travis Hoium	King Pharmaceuticals Shares Popped: What You Need to Know King Pharmaceuticals shares are up nearly 40% today after it was announced the company would be purchased by Pfizer Inc.
The Motley Fool November 2, 2007 Brian Lawler	A Date With Pain Pain Therapeutics prepares for a busy fourth quarter; shares have risen 30% recently in anticipation of upcoming phase 3 data results on oxycodone compound Remoxy. Investors, take note.
The Motley Fool October 8, 2007 Charly Travers	Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics...
The Motley Fool December 31, 2010 Brian Orelli	How the Other Half of Pharma Lives A dive into spec pharma.
The Motley Fool August 31, 2007 Brian Lawler	4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals.
Pharmaceutical Executive June 1, 2006 Sara Calabro	King Without the Crown While most of pharma tries to convince the world that R&D is the number-one priority, one specialty company, King Pharmaceuticals, boasts that it has no lab.
The Motley Fool March 1, 2007	Profit at King Pharmaceuticals: Fool by Numbers The drugmaker released earnings for the fourth-quarter 2006: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool May 5, 2008 Brian Lawler	Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week.
The Motley Fool February 28, 2007 Brian Lawler	Alpharma's Just All Right Drugmaker Alpharma announces its fourth-quarter financial results and reiterates guidance for 2007.
The Motley Fool October 29, 2004 Bill Mann	King, Knave, or Village Idiot? Troubled King Pharmaceuticals' latest accounting woes threaten to scuttle its merger with Mylan.
The Motley Fool November 10, 2006	Sales Down at King Pharmaceuticals: Fool by Numbers The pharmaceutical released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool July 20, 2006 Stephen D. Simpson	Wyeth Wins Again Another respectable quarter and a decent pipeline make this pharmaceutical stock worth watching.
The Motley Fool January 6, 2012 David Williamson	Durect Investors Feel the Pain A phase 3 failure of a lead drug crushes shares.
The Motley Fool April 26, 2011 Brian Orelli	We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants.
The Motley Fool January 21, 2009 Brian Orelli	Pharma Foe Speaks Up for Investors Some good ideas for President Obama's new Food and Drug Administration chief that would benefit investors in drug companies.
The Motley Fool February 27, 2004 Zeke Ashton	King Makes a Comeback The love/hate cycle might be ready to shift again for this pharmaceutical. King Pharmaceuticals was once a beloved growth stock. Then it became an unloved drug stock suffering from intensifying competition, a poor acquisition or two, and an ongoing SEC investigation. The stock has started to come back.
The Motley Fool January 25, 2008 Brian Orelli	Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that.
The Motley Fool October 4, 2007 Billy Fisher	Isis Keeps Cholesterol Down, Stock Prices Up Isis Pharmaceuticals reports positive phase 2 results for a cholesterol treatment. The company continues to show progress with its impressive pipeline of 17 other development-stage drugs. Investors, take note.
The Motley Fool April 20, 2007 Billy Fisher	Many Ways to Feel Good About Wyeth The drugmaker's pipeline makes investors look forward to the next few quarters, too.
The Motley Fool September 26, 2007 Brian Orelli	4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies...
The Motley Fool March 21, 2007 Brian Lawler	New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary.
The Motley Fool June 20, 2011 Brian Orelli	Pfizer's Pain-Free FDA Approval. More to Come? Oxecta gains FDA approval. Remoxy is up next.
The Motley Fool June 27, 2011 Brian Orelli	Double Ouch! 2 Monster Drops in 2 Trading Days Perhaps investors in Pain Therapeutics and DURECT would have rather been kept in the dark about these FDA rejections.
BusinessWeek June 14, 2004 Gene G. Marcial	From Pain Therapeutics: A Better Pain Killer Remoxy, now in proof-of-concept trials, could become the replacement for the most popular opioid pain killer OxyContin, with a potential $1 billion market.
The Motley Fool October 9, 2007 Brian Lawler	Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises.
The Motley Fool December 9, 2008 Brian Orelli	Presents or Coal From the FDA? Let's take a look at a few companies expecting FDA decisions this month and see whether they're more likely to get a present or a lump of coal in their marketing-application stockings.
The Motley Fool October 30, 2006 Brian Lawler	Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
The Motley Fool July 24, 2007 Brian Lawler	Pain and Alpharma Gain From Purdue's Slip Purdue Frederick Company pays a high price for misleading the public about its pain drug OxyContin; other drugmakers stand to benefit from it.
The Motley Fool March 30, 2005 David Nierengarten	Soothing Results, But Pain for Investors Pain Therapeutics delivers again but its stock barely budged. What gives?